China’s radiopharmaceuticals on expressway: 2014–2021
Xi‐Yang Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhibo Liu(Beijing National Laboratory for Molecular Sciences), Haocheng Tang(Sun Yat-sen University), Juan Diwu(Soochow University), Mengchao Cui(Beijing Normal University), Yu Liu(Sichuan University), Yichen Li(Beijing National Laboratory for Molecular Sciences), Zihao Wen(Peking University), Yuchuan Yang(China Academy of Engineering Physics), Changlun Wang(Peking University)
Cited by 11
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
A corrosion-resistant RuMoNi catalyst for efficient and long-lasting seawater oxidation and anion exchange membrane electrolyzer
|Nature Communications|2023|483
LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer
|Cell Death and Disease|2015|205
Covalent targeted radioligands potentiate radionuclide therapy
|Nature|2024|165